溃疡性结肠炎患者对粪菌移植应答相关的特定细菌与代谢物
一项双盲随机对照试验纳入81例活动性溃疡性结肠炎患者,比较强化多供体粪菌移植与安慰剂灌肠诱导缓解的效果,并分析粪便和结肠黏膜样本中与缓解相关的细菌分类及功能因素。结果显示缓解者具有埃氏真杆菌和罗斯氏菌等富集及短链脂肪酸合成增加,未缓解者富集梭杆菌等,供体菌群特征与应答相关。
要点
- 粪菌移植可增加活动性溃疡性结肠炎患者的微生物多样性并改变菌群组成。
- 缓解者粪便和结肠样本中埃氏真杆菌和罗斯氏菌富集,短链脂肪酸合成及次级胆汁酸水平升高。
- 未缓解者富集梭杆菌、萨特氏菌和埃希菌,血红素及脂多糖合成增加。
核心结论
- 在活动性溃疡性结肠炎患者中,特定细菌和代谢通路与粪菌移植诱导缓解相关,这些发现可能对设计基于微生物的疗法有价值。
研究设计与样本
- 双盲随机对照试验纳入81例活动性溃疡性结肠炎患者,随机接受初始结肠镜灌注后强化多供体粪菌移植或安慰剂灌肠,每周5天共8周。
- 粪菌移植组接受来自3至7名无关供体的混合匀浆粪便;安慰剂组在双盲期后可接受开放标签粪菌移植。
- 收集患者314份粪便样本(筛查时、治疗期间每4周、盲法或开放标签粪菌移植后8周)和160份大肠活检样本(研究开始时、8周盲法治疗完成时及开放标签粪菌移植结束时)。
- 分析来自14名供体的105份粪便样本(n=55),这些供体贡献了21个多供体批次(n=50)。
主要发现
- 粪菌移植增加了微生物多样性并改变组成,基于粪菌移植前后收集的结肠和粪便样本分析。
- 达到缓解的患者在粪菌移植前后收集的粪便和结肠样本中多样性均高于未达到缓解的患者。
- 粪菌移植后缓解的患者中埃氏真杆菌和罗斯氏菌富集,短链脂肪酸生物合成和次级胆汁酸水平增加, compared with 未达到缓解的患者。
- 未达到缓解的患者中梭杆菌、萨特氏菌和埃希菌富集,血红素和脂多糖生物合成水平增加。
- 供体粪便中的拟杆菌属与接受粪菌移植患者的缓解相关,供体粪便中的链球菌属与无应答相关。
关键数值与推荐
- 285份粪便样本进行了鸟枪法宏基因组学分析,60份粪便样本进行了代谢组学特征分析。
- 结肠和粪便样本中的细菌通过16S核糖体RNA基因和转录本扩增子测序分析。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Fecal microbiota transplantation (FMT) can induce remission in patients with ulcerative colitis (UC). In a randomized controlled trial of FMT in patients with active UC, we aimed to identify bacterial taxonomic and functional factors associated with response to therapy. METHODS: We performed a double-blind trial of 81 patients with active UC randomly assigned to groups that received an initial colonoscopic infusion and then intensive multidonor FMT or placebo enemas, 5 d/wk for 8 weeks. Patients in the FMT group received blended homogenized stool from 3-7 unrelated donors. Patients in the placebo group were eligible to receive open-label FMT after the double-blind study period. We collected 314 fecal samples from the patients at screening, every 4 weeks during treatment, and 8 weeks after the blinded or open-label FMT therapy. We also collected 160 large-bowel biopsy samples from the patients at study entry, at completion of 8 weeks of blinded therapy, and at the end of open-label FMT, if applicable. We analyzed 105 fecal samples from the 14 individual donors (n = 55), who in turn contributed to 21 multidonor batches (n = 50). Bacteria in colonic and fecal samples were analyzed by both 16S ribosomal RNA gene and transcript amplicon sequencing; 285 fecal samples were analyzed by shotgun metagenomics, and 60 fecal samples were analyzed for metabolome features. RESULTS: FMT increased microbial diversity and altered composition, based on analyses of colon and fecal samples collected before vs after FMT. Diversity was greater in fecal and colon samples collected before and after FMT treatment from patients who achieved remission compared with patients who did not. Patients in remission after FMT had enrichment of Eubacterium hallii and Roseburia inulivorans compared with patients who did not achieve remission after FMT and had increased levels of short-chain fatty acid biosynthesis and secondary bile acids. Patients who did not achieve remission had enrichment of Fusobacterium gonidiaformans, Sutterella wadsworthensis, and Escherichia species and increased levels of heme and lipopolysaccharide biosynthesis. Bacteroides in donor stool were associated with remission in patients receiving FMT, and Streptococcus species in donor stool was associated with no response to FMT. CONCLUSIONS: In an analysis of fecal and colonic mucosa samples from patients receiving FMT for active UC and stool samples from donors, we associated specific bacteria and metabolic pathways with induction of remission. These findings may be of value in the design of microbe-based therapies for UC. ClinicalTrials.gov, Number NCT01896635.
引用
- Paramsothy S, Nielsen S, Kamm MA, et al. Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis. Gastroenterology. 2018. PMID: 30529583. doi:10.1053/j.gastro.2018.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。